A Pilot Study to Evaluate PureWick for Nocturia
Primary Purpose
Nocturia
Status
Suspended
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PureWick System
Sponsored by
About this trial
This is an interventional treatment trial for Nocturia
Eligibility Criteria
Inclusion Criteria:
- Women aged 50 years or older.
- Experiences 2 or more voids per night as assessed on a 3-day bladder diary.
Exclusion Criteria:
- Compromised skin integrity in the perineal area (e.g., ulcers, open wounds, etc.).
- Neurological impairment or psychiatric disorder preventing proper understanding of consent.
- Unable to operate the PureWick system.
- Unable to complete required questionnaires and diaries.
- Investigator deems subject as unsuitable for enrollment.
Sites / Locations
- Weill Cornell Medicine
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
The PureWick Urine Collection System
Arm Description
The PureWick Urine Collection System is intended for non-invasive urine output management. It pulls urine through tubing that is connected to a collection canister for proper disposal. It is designed to be used by patients, caregivers, or healthcare professionals in both home environments and professional care facilities.
Outcomes
Primary Outcome Measures
The proportion of patients at 3 months who have a demonstrated 50% or greater reduction in the number of nocturia episodes/night
The proportion of patients at 3 months who have a demonstrated 50% or greater reduction in the number of nocturia episodes/night will be calculated via binomial proportions and an exact (Clopper-Pearson) 95% confidence interval will be computed to assess the precision of the obtained estimate.
Change in average number of nocturnal voids at baseline and at 3 months
The paired t-test or Wilcoxon signed-rank test will be used, as appropriate, to compare the average number of nocturnal voids between baseline and at 3 months.
Change of scores on the N-QoL at baseline and at 3-months
N-QoL (Nocturia quality of life) score is determined by the n-qol short form. The ICIQ-Nqol is a patient-completed questionnaire evaluating quality of life (QoL) in patients with nocturia for use in research and clinical practice across the world. The ICIQ-Nqol is the N-QoL adapted for use within the ICIQ structure and provides a detailed and robust measure to assess the impact of nocturia on quality of life with particular reference to the effects on patient' lives of Nocturia and can be used as an outcome measure to assess impact of different treatment modalities.
0-52 overall score with greater values indicating increased impact on quality of life Bother scale not incorporated into overall score but indicate impact of symptoms overall for the patient.
Similar analyses to paired t-test or Wilcoxon signed-rank test will be performed to compare scores on the N-QoL, an self-reported sleep quality between baseline and at 3-months.
Secondary Outcome Measures
Change in the incidence of urinary tract infection (UTI) at baseline and 3 months
McNemar's chi-square test will be used to compare the incidence of UTI between baseline and at 3 months.
Change in the incidence of pressure ulcers/skin breakdown at baseline and 3 months
McNemar's chi-square test will be used to compare pressure ulcers/skin breakdown between baseline and at 3 months.
Full Information
NCT ID
NCT05090722
First Posted
October 12, 2021
Last Updated
October 12, 2023
Sponsor
Weill Medical College of Cornell University
Collaborators
Becton, Dickinson and Company
1. Study Identification
Unique Protocol Identification Number
NCT05090722
Brief Title
A Pilot Study to Evaluate PureWick for Nocturia
Official Title
A Pilot Study to Evaluate PureWick for Nocturia
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Suspended
Why Stopped
Principal Investigator changing locations.
Study Start Date
December 16, 2021 (Actual)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
October 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Weill Medical College of Cornell University
Collaborators
Becton, Dickinson and Company
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a single-center prospective pilot study of PureWick used as a management for nocturia and reduction of nighttime falls associated with going to the bathroom. Subjects are followed up to 3 months after the intervention. As a pilot study, it is expected that a 3-month follow-up will adequately capture urinary and sleep outcomes data and any adverse events related or unrelated to the study device.
Detailed Description
Nocturia is a highly prevalent condition among older adults, significantly affecting the quality of life as well as putting them at an increased risk of falls and fractures. In those 65 and older, accidental falls are identified as the leading cause of injury and death. The chance of falling increases from 30% to 50% with age greater than 85 years.
A study identified that in 1508 ambulatory men and women, nighttime urination of 2 times at night is associated with increased risk of falls (OR=1.84, 95% CI 1.05-3.22), with significantly higher risks when it increased to 3 or more times at night (OR=2.15, CI 95% -1.04-4.44). Incontinence management that reduces the need to get out of bed will lead to reduced risk of falls and unintentional injury fatalities.
The PureWick Urine Collection System is intended for non-invasive urine output management. It pulls urine through tubing that is connected to a collection canister for proper disposal. It is designed to be used by patients, caregivers, or healthcare professionals in both home environments and professional care facilities.
The PureWick System allows individuals to void while still in bed, demonstrating the potential to reduce the risks of falls associated with nighttime voids in men and women with nocturia. We hypothesize that this will also improve sleep quality and overall quality of life.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nocturia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
The PureWick Urine Collection System
Arm Type
Experimental
Arm Description
The PureWick Urine Collection System is intended for non-invasive urine output management. It pulls urine through tubing that is connected to a collection canister for proper disposal. It is designed to be used by patients, caregivers, or healthcare professionals in both home environments and professional care facilities.
Intervention Type
Device
Intervention Name(s)
PureWick System
Other Intervention Name(s)
PureWick Urine Collection System device, PWF030F
Intervention Description
The PureWick system consists of the external catheter, collection tubing, and collection canister with lid. It operates via a power cord that is plugged into the device outlet and the A/C power outlet.
Primary Outcome Measure Information:
Title
The proportion of patients at 3 months who have a demonstrated 50% or greater reduction in the number of nocturia episodes/night
Description
The proportion of patients at 3 months who have a demonstrated 50% or greater reduction in the number of nocturia episodes/night will be calculated via binomial proportions and an exact (Clopper-Pearson) 95% confidence interval will be computed to assess the precision of the obtained estimate.
Time Frame
3 months
Title
Change in average number of nocturnal voids at baseline and at 3 months
Description
The paired t-test or Wilcoxon signed-rank test will be used, as appropriate, to compare the average number of nocturnal voids between baseline and at 3 months.
Time Frame
At baseline and 3 months
Title
Change of scores on the N-QoL at baseline and at 3-months
Description
N-QoL (Nocturia quality of life) score is determined by the n-qol short form. The ICIQ-Nqol is a patient-completed questionnaire evaluating quality of life (QoL) in patients with nocturia for use in research and clinical practice across the world. The ICIQ-Nqol is the N-QoL adapted for use within the ICIQ structure and provides a detailed and robust measure to assess the impact of nocturia on quality of life with particular reference to the effects on patient' lives of Nocturia and can be used as an outcome measure to assess impact of different treatment modalities.
0-52 overall score with greater values indicating increased impact on quality of life Bother scale not incorporated into overall score but indicate impact of symptoms overall for the patient.
Similar analyses to paired t-test or Wilcoxon signed-rank test will be performed to compare scores on the N-QoL, an self-reported sleep quality between baseline and at 3-months.
Time Frame
At baseline and 3 months
Secondary Outcome Measure Information:
Title
Change in the incidence of urinary tract infection (UTI) at baseline and 3 months
Description
McNemar's chi-square test will be used to compare the incidence of UTI between baseline and at 3 months.
Time Frame
At baseline and 3 months
Title
Change in the incidence of pressure ulcers/skin breakdown at baseline and 3 months
Description
McNemar's chi-square test will be used to compare pressure ulcers/skin breakdown between baseline and at 3 months.
Time Frame
At baseline and 3 months
10. Eligibility
Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Women aged 50 years or older.
Experiences 2 or more voids per night as assessed on a 3-day bladder diary.
Exclusion Criteria:
Compromised skin integrity in the perineal area (e.g., ulcers, open wounds, etc.).
Neurological impairment or psychiatric disorder preventing proper understanding of consent.
Unable to operate the PureWick system.
Unable to complete required questionnaires and diaries.
Investigator deems subject as unsuitable for enrollment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bilal Chughtai, MD
Organizational Affiliation
Weill Medical College of Cornell University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Weill Cornell Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
19463079
Citation
Chiarelli PE, Mackenzie LA, Osmotherly PG. Urinary incontinence is associated with an increase in falls: a systematic review. Aust J Physiother. 2009;55(2):89-95. doi: 10.1016/s0004-9514(09)70038-8.
Results Reference
background
Citation
Centers for Disease Control and Prevention, N.C.f.I.P.a.C. Web-based Injury Statistics Query and Reporting System (WISQARS). December 7, 2014].
Results Reference
background
PubMed Identifier
23074507
Citation
Medical Advisory Secretariat. Prevention of falls and fall-related injuries in community-dwelling seniors: an evidence-based analysis. Ont Health Technol Assess Ser. 2008;8(2):1-78. Epub 2008 Oct 1.
Results Reference
background
PubMed Identifier
23672343
Citation
Hunter KF, Voaklander D, Hsu ZY, Moore KN. Lower urinary tract symptoms and falls risk among older women receiving home support: a prospective cohort study. BMC Geriatr. 2013 May 15;13:46. doi: 10.1186/1471-2318-13-46.
Results Reference
background
PubMed Identifier
29394218
Citation
Beeson T, Davis C. Urinary Management With an External Female Collection Device. J Wound Ostomy Continence Nurs. 2018 Mar/Apr;45(2):187-189. doi: 10.1097/WON.0000000000000417.
Results Reference
background
Learn more about this trial
A Pilot Study to Evaluate PureWick for Nocturia
We'll reach out to this number within 24 hrs